Healthcare Edge – ExecEdge

Agendia Reports Findings for Breast Cancer Treatment

Agendia Reports Findings for Breast Cancer Treatment

By Karen Roman Agendia, Inc., a biotechnology company that provides molecular diagnostics and cancer treatment, said it can predict response and nonresponse to common neoadjuvant immunotherapy for patients with triple negative breast cancer. Agendia holds an FDA Investigational Device Exempt...

Conduit Pharmaceuticals Adds Key Leadership Positions

Conduit Pharmaceuticals Adds Key Leadership Positions

By Daniella Parra Conduit Pharmaceuticals Inc. (Nasdaq: CDT) announced the appointment of Dr. Joanne Holland as Chief Scientific Officer and Dr. Jeff Lindeman as a Consultant on intellectual property strategies. The company said Dr. Holland brings over 20 years of...

Conduit Pharmaceuticals Opens New Laboratory in UK

Conduit Pharmaceuticals Opens New Laboratory in UK

By Karen Roman Conduit Pharmaceuticals Inc. (Nasdaq: CDT), a clinical-stage life science company, reported it has opened a new cutting-edge laboratory space in Cambridge, U.K. This new facility sits within a space of 150 acres and 2 million square feet...

Promontory Therapeutics Enrolls 109 Patients in Prostate Cancer Study

Promontory Therapeutics Enrolls 109 Patients in Prostate Cancer Study

By Daniella Parra Promontory Therapeutics Inc. completed enrollment of 109 late-stage metastatic castration-resistant prostate cancer patients for its Phase 2 trial of PT-112, which assesses its efficacy in patients who have undergone prior treatments, the company said. PT-112 is a...

Sparrow Pharmaceuticals’ PROST! Adds a Fourth Cohort

Sparrow Pharmaceuticals’ PROST! Adds a Fourth Cohort

By Daniella Parra Sparrow Pharmaceuticals continues its PROST! Phase 2 clinical trial for treating polymyalgia rheumatica (PMR) with SPI-62 and prednisolone, adding a fourth cohort, they said. PMR, an autoimmune disorder common among the elderly, traditionally treated with steroids like...

Apollomics Names Matthew Plunkett as Chief Financial Officer

Apollomics Names Matthew Plunkett as Chief Financial Officer

By Karen E. Roman Apollomics, Inc. (Nasdaq: APLM), a biopharmaceutical company that develops medicines for difficult-to-treat cancers, said it appointed Matthew Plunkett, Ph.D., as Chief Financial Officer. Dr. Plunkett has over 25 years of strategic and financial experience within the...

FIGS 4Q Adjusted EBITDA Climbs $6.8 Million

FIGS 4Q Adjusted EBITDA Climbs $6.8 Million

By Daniella Parra FIGS, Inc. (NYSE: FIGS) said fourth quarter net revenue was $144.9 million and a reclassification negatively impacted net revenues by $4.7 million. Gross margin was 67.5%, a decrease of 70 basis points and operating expenses were $83.6...

Vivani Medical Shows Preclinical Data on Weight Loss Implants

Vivani Medical Shows Preclinical Data on Weight Loss Implants

By Daniella Parra Vivani Medical, Inc. (Nasdaq: VANI) reported promising preclinical data on NPM-115, a miniature exenatide implant for chronic weight management. The company focuses on GLP-1 implants for obesity treatment due to their potential to improve patient outcomes, which...

Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels

Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it demonstrated that VXX-401 lowers LDL cholesterol, supporting its potential for treating hypercholesterolemia. The VXX-401, a synthetic peptide vaccine, aims to provide a safe and effective solution against heart disease by targeting...

Input your search keywords and press Enter.